for Parkinson's disease and Restless Legs Syndrome, how well does it work?
September 10 2017 by Ray Sahelian, M.D.
Requip (ropinirole hydrochloride) is an orally administered non-ergoline dopamine agonist.
The need for multiple administrations and a difficult titration schedule has always represented a limit in the use of dopamine agonists in the treatment of early Parkinson's disease. To avoid these problems, Ropinirole prolonged release, a non-ergoline dopamine receptor agonist that can be taken once a day, has been formulated. The prolonged release formulation has higher patient compliance due to a simpler and fastest titration schedule; the once-a-day administration makes this molecule especially suitable for young Parkinsonian patients who are still working and having an active lifestyle.
Requip for Parkinson's disease
Requip is prescribed for the treatment of Parkinsonís disease.
treatment is associated with the development of motor fluctuations and peak dose
dyskinesias. Dopamine Replacement Therapy (DRT) with dopamine agonists (DAs) (ropinirole
and pramipexole) is used to manage complications of L-dopa treatment.
Requip for restless legs syndrome
Requip is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
Ropinirole prolonged release in advanced Parkinson's disease
Requip Ropinirole prolonged release is a dopamine receptor agonist that is indicated for the treatment of Parkinson's disease. Once-daily Requip prolonged release and three-times-daily immediate release have similar exposure over 24 hours. The prolonged-release formulation is associated with fewer fluctuations in plasma Requip concentrations. Requip prolonged release 6-12 mg once daily is generally well tolerated in patients with advanced Parkinson's disease; adverse events are generally typical of non-ergoline dopamine receptor agonists.